Evotec
Dr. Christine Guenther is an accomplished leader in the field of cell therapy and regenerative medicine, currently serving as the Executive Vice President and Head of Global Cell Therapy Translation at Evotec since February 2021. With extensive experience, Dr. Guenther has shaped Evotec's Cell Therapy business unit and managed its Cell Factory in Modena, Italy, focusing on the clinical application of iPSC-derived cell types and ensuring regulatory compliance. Previously, Dr. Guenther was the CEO and Chief Medical Officer at Minaris Regenerative Medicine, where notable achievements include leading the development and manufacturing of complex cell and gene therapies. Dr. Guenther holds a Ph.D. in Medicine from Ludwig-Maximilians-Universität München and has a robust background in hematology and oncology, including roles as a Medical Director and in quality control in various organizations.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.